Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taiwan Expected To Approve Soon Nation's First Weight-loss Drug

This article was originally published in PharmAsia News

Executive Summary

Taiwan's Bureau of Pharmaceutical Affairs is expected to give the go-ahead to GlaxoSmithKline to market its Alli (orlistat) drug to people seeking to lose weight in Taiwain. The BPA has reviewed safety aspects of the drug, but an official warns potential patients need to remember Alliis a drug and should be handled with precaution. The official suggested GSK might have to provide an easy-to-read leaflet describing side effects of the drug and a requirement pharmacists explain its use. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072453

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel